One moment, please...
satellite.bio
Actively hiring
As featured in
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
News
Satellite Bio Announces FDA Clearance of IND Application for SB-101 for the Treatment of Urea Cycle Disorders (UCDs) Marking its Transition to a Clinical-Stage Biotechnology Company
NEWTON, Mass., August 04, 2026--Satellite Biosciences, Inc. (Satellite Bio), a clinical-stage biotechnology company developing off-the-shelf liver therapies designed to restore liver function in patients with severe liver diseases, today announced that th
Read more
Report
Satellite Bio Announces FDA Clearance of IND Application for SB-101 for the Treatment of Urea Cycle Disorders (UCDs) Marking its Transition to a Clinical-Stage Biotechnology Company
Satellite Bio Announces FDA Clearance of IND Application for SB-101 for the Treatment of Urea Cycle Disorders (UCDs) Marking its Transition to a Clinical-Stage Biotechnology Company
Read more
Report
Satellite Bio Announces FDA Rare Pediatric Disease Designation for SB-101 for the Treatment of Urea Cycle Disorders (UCDs)
NEWTON, Mass., May 04, 2026--Satellite Biosciences, Inc. (Satellite Bio), a biotechnology company developing off-the-shelf liver therapies designed to restore liver function in patients with severe liver diseases, today announced that the U.S. Food and Dr
Read more
Report